HC Wainwright & Co. Maintains Buy on Nuvation Bio, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Nuvation Bio but lowered the price target from $8 to $7.

September 16, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Nuvation Bio but lowered the price target from $8 to $7, indicating a slightly less optimistic outlook.
The maintenance of a Buy rating suggests continued confidence in Nuvation Bio's prospects, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100